obesity drug news today glp-1 october 21 2025 Market Study identifies benefits, risks linked

Notably, Huang et al

Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade

As the insulinotropic effects are glucose-dependent and the counterregulatory response of glucagon to hypoglycaemia remains intact with GLP-1 infusion [19], the risk of hypoglycaemia is low

An updated literature review

Metaflammation in obesity and its therapeutic targeting

Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease